Germline mutations in CDH1, encoding E-cadherin, are known to be the causative mechanism of hereditary diffuse gastric cancer (HDGC). We encountered two cases of gastric cancer in a Japanese family with HDGC. A 28-year-old man (Case 1) died of advanced gastric cancer. His younger sister aged 27 (Case 2) was diagnosed with intramucosal signet ring cell carcinoma (SRCC). Both had identical germline CDH1 mutations, but Case 1 was positive for Helicobacter pylori infection, whereas Case 2 was negative. Case 2 underwent total gastrectomy. Whole-exome sequencing of an intramucosal SRCC in Case 2 revealed seven somatic mutations including one in CDH1. The six non-CDH1 mutations were classified as non-driver mutations. Decreased expression of E-cadherin in intramucosal SRCC was confirmed by immunohistochemistry. Our report demonstrated that CDH1 mutation was the only active driver mutation in Helicobacter pylori-uninfected intramucosal SRCC.
Introduction
Hereditary diffuse gastric cancer (HDGC) is an inherited form of gastric cancer. Approximately 40% of HDGC patients have germline mutations in CDH1, which encodes E-cadherin [1] . E-cadherin is a calcium-dependent cell membrane protein involved in cell-cell adhesion that is a known tumor suppressor. The cumulative risk of diffuse gastric cancer in HDGC patients with germline CDH1 mutations is approximately 70% for men and 56% for women [2] . The distinctive microscopic feature of early gastric cancer in family members with HDGC is multiple foci of intramucosal signet ring cell carcinoma (SRCC) [3] [4] [5] [6] . Although the role of CDH1 mutations in HDGC has been well studied [1, 7] , little is known about the genetic alterations in intramucosal SRCC.
Here, we present two patients with early-onset HDGC belonging to a Japanese family with HDGC. Whole-exome sequencing (WES) of an intramucosal SRCC from one patient was performed to clarify the carcinogenic mechanism of HDGC.
Case presentation

Case 1
A 27-year-old man presented with abdominal pain. Esophagogastroduodenoscopy (EGD) revealed advanced infiltrative gastric cancer at the greater curvature of upper gastric body on a background of atrophic gastric mucosa (Fig. 1a,  b) . Histopathological examination using a biopsy specimen revealed poorly differentiated adenocarcinoma (Fig. 1c) . Immunohistochemical analysis for Helicobacter pylori (Hp) was positive. Abdominal computed tomography demonstrated peritoneal dissemination (Fig. 1d) . The patient was given a diagnosis of unresectable advanced gastric cancer. He received palliative chemotherapy but died of the disease 9 months after the initiation of chemotherapy.
Case 2
A 27-year-old woman (the younger sister of Case 1) underwent surveillance EGD and was found to have an intramucosal gastric cancer in the middle gastric body on a background of nonatrophic gastric mucosa (Fig. 2a, b, c, d ). Serum antibody for Hp and immunohistochemical analysis for Hp were negative. She had no history of Hp eradication therapy. These results strongly suggested that she was Hp-uninfected. She underwent total gastrectomy (Fig. 3) .
The presence of intramucosal SRCC with no component of poorly differentiated adenocarcinoma (Fig. 3, lesion 1) , which was detected by surveillance EGD, was confirmed by histology (Fig. 4a, b) . In addition, two other intramucosal SRCCs that could not be detected before surgery were also found in the prepylorus (Figs. 2d, 3 ). Decreased expression of E-cadherin (Fig. 4c ) and an absence of nuclear accumulation of P53 (Fig. 4d) of the lesion 1 were confirmed by immunohistochemistry.
Genetic analysis
Presence of a germline CDH1 mutation
The two patients (Cases 1 and 2) had several family members with a history of gastric cancer (Fig. 5) , which according to the International Gastric Cancer Linkage Consortium clinical criteria for HDGC, raised the possibility that they were a family at risk of HDGC [8] , especially because their father also had a history of gastric cancer. Therefore, the patients and their father were offered genetic counseling and were tested for CDH1 mutations. DNA was extracted from their peripheral blood. Combination of polymerase chain reaction-direct sequencing analysis and multiplex ligationdependent probe amplification was performed for all the exons of CDH1 as described previously [7] . This genetic testing revealed an identical germline CDH1 mutation (nonsense mutation at exon 3, c.187C>T; p.R63 * ) in both the patients and their father. This family had the strongest family history of gastric cancer compared to four HDGC families previously reported in Japan [5] [6] [7] .
Presence of a somatic CDH1 mutation in the intramucosal SRCC of Case 2
To characterize the molecular basis of the development of SRCC, we performed WES of the resected specimen. Written informed consent was obtained according to protocols approved by the Ethics Committee of Kyoto University. Genomic DNA was isolated from the intramucosal SRCC (Fig. 3 , lesion 1) in formalin-fixed paraffin-embedded tissue and from a matched peripheral blood sample using GeneRead DNA FFPE Kit and DNeasy Blood and Tissue Kit (Qiagen), respectively. DNA libraries were prepared using SureSelect Human All Exon V5 (Agilent Technologies) and were sequenced using an Illumina HiSeq 2500 platform. Mutation calling was performed using the Genomon pipeline (http:// genom on.hgc.jp/exome /en/index .html). Candidate mutations were validated by polymerase chain reaction-based amplicon deep sequencing using matched biopsy sample from the intramucosal SRCC [9] . The results identified seven somatic mutations; a CDH1 mutation (missense mutation at exon 5, c.641T>C; p.L214P) and other six non-driver mutations (Table 1) , in addition to the germline mutation (nonsense mutation at exon 3, c.187C>T; p.R63 * ) that was identical to those found in the DNA from peripheral blood of the two family members (Case 1 and their father). Fig. 3 ) Fig. 3 Gastrectomy mapping study of Case 2. Red lines indicate foci of intramucosal SRCC. The main lesion is indicated by line 1 (lesion 1). Two other intramucosal SRCCs (lesion 2 and 3 indicated by line 2 and 3, respectively) that could not be detected before surgery were found in the prepylorus
Discussion
To our knowledge, this is the first study showing the results of WES of the intramucosal SRCC specimen in family members with HDGC. Although the role of germline mutations of CDH1 in HDGC has been well studied, little is known about the genetic alterations in intramucosal SRCC, because these tumors are very small and it is difficult to obtain a sufficient amount of DNA.
We were able to perform WES of an intramucosal SRCC in Case 2, the results of which revealed a germline and a somatic mutation of CDH1 that were both pathogenic: the germline mutation was a nonsense mutation of exon 3 [10] , which encodes the precursor of E-cadherin, resulting in the expression of truncated non-functional protein. On the other hand, the somatic mutation was a missense mutation of exon 5, c.641T>C and p.L214P, which has been reported in the analysis of gastric cancer [11, 12] and to affect protein function in vitro [13] . Although the possibility that these two mutations are present on the same allele cannot be excluded, the somatic mutation could lead to inactivation of the protein encoded by the remaining wild-type CDH1 allele through a second-hit mechanism, resulting in a loss of E-cadherin function. Indeed, immunohistochemical analysis confirmed that E-cadherin expression was impaired in the intramucosal SRCC contrasting to adjacent normal epithelium, suggesting loss of E-cadherin function.
However, our analysis showed other six mutations in addition to those in CDH1. These mutations have not been reported as active driver mutations in the comprehensive molecular analyses of gastric cancer [12, [14] [15] [16] [17] . Moreover, they could not be identified in any other types of tumor during the search of the COSMIC v86 database (https ://cance r.sange r.ac.uk/cosmi c). These results strongly suggest that these six mutations are unlikely to be driver mutations.
We emphasize that only a small number of mutations were detected in the intramucosal SRCC. For example, there was no mutation in TP53, one of the most frequently 1 3 mutated oncogenes in gastric cancer. These results are in agreement with the Cancer Genome Atlas database, which shows that CDH1 mutations are often observed in 'genomically stable' groups characterized by a diffuse histological subtype with a low frequency of genetic mutations, including in TP53 [17] .
The Hp infection status of the patients in this study deserves attention. Both Cases 1 and 2 had similar earlyonset HDGC, the difference being that Case 1 was Hpinfected and had advanced-stage cancer while Case 2 was Hp-uninfected and had intramucosal SRCCs. It has been reported that various latent mutations including some in TP53 accumulate in the gastric mucosa of patients with Hp infection [18] . Unfortunately, we could not perform genetic analysis of the tumor tissue of Case 1 because of the small amount of DNA available. However, we speculate that some additional driver mutations such as TP53 mutation caused by Hp infection contributed to the acquisition of the invasive phenotype of the cancer in Case 1. In a mouse model, E-cadherin deficiency alone is sufficient to develop the gastric SRCC [19, 20] . A recent study clarified that stem cell-specific E-cadherin deficiency alone could develop SRCC foci transiently and additive Helicobacter felis infection could maintain these foci [21] . However, it is unknown whether these foci could acquire an invasive and metastatic phenotype in the future. On the other hand, it has been reported that invasive and metastatic diffuse-type gastric cancer developed in stem cell or parietal cell-specific Cdh1 and Trp53 double-knockout mice [21, 22] . Our report involving two siblings with HDGC may strongly support the results of previous animal experiments. 5 Family tree of this family with HDGC including Cases 1 and 2. The shaded square and circle represent the family members with gastric cancer. GC age at diagnosis of gastric cancer; E+ CDH1 mutation positive; E− CDH1 mutation negative, P Proband In Japan, gastric cancer is the most common cancer and the third leading cause of cancer death. Although most gastric cancers in Japan are caused by Hp infection [23] , the prevalence of Hp infection in Japan has declined in recent years [24, 25] and the relative frequency of Hp-uninfected gastric cancer may be increasing. Recently, cases of mucosal SRCC without Hp infection are accumulating [26, 27] . Interestingly, the histopathology of Case 2 closely resembled a typical case of Hp-uninfected SRCC. In this regard, the results of the genetic analysis in Case 2 may be informative for clarifying the mechanism of carcinogenesis of Hpuninfected SRCC. However, further studies are required to identify the genetic alterations in sporadic Hp-uninfected gastric cancer.
In conclusion, we report a family with HDGC containing two members with early-onset gastric cancer diagnosed at different stages who had different Hp infection status. Our results of the genetic analysis demonstrated that CDH1 mutation was the only active driver mutation in Hp-uninfected intramucosal SRCC.
